NCT06511063View on ClinicalTrials.gov

Antiviral Clinical Trial for Long Covid-19

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Long Covid
Interventions
DRUG

tenofovir disoproxil/emtricitabine

Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.

DRUG

Selzentry

Participants will take Selzentry for 90 days.

DRUG

Placebo

Matching placebo.

Trial Locations (1)

10029

RECRUITING

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York

Sponsors
All Listed Sponsors
collaborator

Yale University

OTHER

collaborator

PolyBio Research Foundation

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER